Paul Marik HAT Sepsis Protocol
Connection to Cancer
The Paul Marik HAT Sepsis Protocol combines hydrocortisone, ascorbic acid/vitamin C, and thiamine for severe sepsis and septic shock. It is not a cancer treatment. Its connection to oncology is supportive and critical-care related: people with cancer can be at higher risk for serious infection because of chemotherapy, neutropenia, central lines, surgery, immune suppression, advanced disease, or hospitalization. When infection progresses to sepsis or septic shock, treatment is an emergency and must follow hospital critical-care standards.
Why It Became Notable
The protocol became widely discussed after a 2017 before-after study by Marik and colleagues reported striking survival differences in severe sepsis and septic shock when hydrocortisone, intravenous vitamin C, and thiamine were used together. The biological rationale included support for endothelial function, capillary leak, catecholamine responsiveness, mitochondrial metabolism, and prevention of oxalate-related complications from high-dose vitamin C through thiamine replacement.
Evidence Snapshot
Later randomized trials and guideline reviews did not reproduce the dramatic early result consistently. Trials such as VITAMINS, VICTAS, ACTS, and LOVIT produced mixed or negative findings, and current sepsis guidelines do not recommend routine intravenous vitamin C for sepsis or septic shock outside appropriate clinical judgment or research settings. Some clinicians and patients still follow the topic closely because the components are familiar, inexpensive, and biologically plausible, while others view the early claims as unconfirmed.
Practical Cautions
Sepsis is life-threatening and time-sensitive. Patients with cancer who develop fever, confusion, low blood pressure, rapid breathing, or signs of infection need urgent medical care. Any use of hydrocortisone, intravenous vitamin C, or thiamine in sepsis belongs under physician-led critical-care supervision, especially in patients with kidney disease, G6PD deficiency, glucose-monitoring issues, active chemotherapy, immunotherapy, anticoagulation, or complex oncology treatment plans.